Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

237.88 +2.61 (+1.11%)
Streaming Delayed Price Updated: 9:57 AM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 556,401
Open 236.80
Bid (Size) 237.81 (300)
Ask (Size) 237.89 (300)
Prev. Close 235.27
Today's Range 235.73 - 237.90
52wk Range 141.50 - 251.71
Shares Outstanding 2,628,679,824
Dividend Yield 2.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Fear Gauge Ascendant: VIX Hits 26 as Geopolitical Storms and 'Higher-for-Longer' Reality Grip Markets
The CBOE Volatility Index (VIX), Wall Street’s premier measure of expected stock market volatility, climbed to a reading of 26.15 this week, marking its highest sustained level in nearly two years. As... 
Via MarketMinute
Topics Derivatives Economy Stocks
News headline image
If You Only Own Tech Stocks, Jim Cramer Has a Blunt Warning for You in 2026 ↗
CNBC commentator Jim Cramer sees value in the artificial intelligence (AI) realm beyond the technology sector. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks

Performance

YTD
+14.7%
+14.7%
1 Month
-3.2%
-3.2%
3 Month
+15.6%
+15.6%
6 Month
+34.7%
+34.7%
1 Year
+45.7%
+45.7%

More News

Read More
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
Via MarketMinute
News headline image
Johnson & Johnson (JNJ) Forecast: Extended Rally Signals Patience for Buyers ↗
Via Talk Markets
News headline image
1 Dividend ETF That Could Turn $500 Monthly Into a $725,000 Portfolio That Pays $21,750 Annually ↗
Via The Motley Fool
Topics ETFs
News headline image
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie ↗
Via Benzinga
News headline image
2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
2 Stocks That Could Create Lasting Generational Wealth ↗
Via The Motley Fool
Topics World Trade
News headline image
The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape
Via MarketMinute
Topics Artificial Intelligence Lawsuit
News headline image
Your Tax Refund Will Probably Be Bigger This Year. Here's What to Do With It. ↗
Via The Motley Fool
Topics Economy Retirement
News headline image
Stryker Corporation (SYK): Navigating Innovation and Resilience in the Wake of a Digital Crisis
Via Finterra
Topics Earnings Economy Hacking
News headline image
Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results ↗
Via Stocktwits
News headline image
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Best Dividend Stocks to Buy and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
1 No-Brainer S&P 500 Vanguard ETF to Buy Right Now for Less Than $1,000 ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Via Finterra
Topics ETFs Intellectual Property
News headline image
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
From Johnson & Johnson
Via Business Wire
News headline image
End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement
Via MarketMinute
Topics Economy Retirement
News headline image
Cracks in the Bull Case: S&P 500 Breaches Key Support as Institutional Distribution Takes Hold
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Safe Haven in a Storm: Healthcare Leads Markets as Geopolitical Tensions Spark Defensive Rotation
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Quiet Outperformance From an Overlooked Dividend ETF ↗
Via MarketBeat
News headline image
2 No-Brainer Dividend Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders ↗
Via The Motley Fool
Topics Artificial Intelligence

Frequently Asked Questions

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded.
What exchange does Johnson & Johnson trade on?
Johnson & Johnson trades on the New York Stock Exchange
What is the ticker symbol for Johnson & Johnson?
The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange
What is the current price of Johnson & Johnson?
The current price of Johnson & Johnson is 237.88
When was Johnson & Johnson last traded?
The last trade of Johnson & Johnson was at 03/25/26 09:57 AM ET
What is the market capitalization of Johnson & Johnson?
The market capitalization of Johnson & Johnson is 625.31B
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson has 625B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.